Deciphera (DCPH) PT Raised to $78 at Guggenheim, Following Clinical Trial Update
Tweet Send to a Friend
Guggenheim analyst Michael W. Schmidt ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
